BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

...and Hongjiang Li, Staff Writers Lupuzor, rigerimod (CEP-33457, ipp-201101, P140, syb l-1001, forigerimod) Pamrevlumab (FG-3019) Revatio, Viagra, sildenafil FibroGen Inc. ImmuPharma plc Jiangsu...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...obexelimab met a secondary endpoint of longer time to loss of improvement (LOI) vs. placebo. ImmuPharma plc...
...based on modified British Isles Lupus Assessment Group (BILAG)-based combined lupus assessment (mBICLA) April 17th ImmuPharma plc...
...which mediates signaling by IFNα and other cytokines. T cell activity: Peptide analog Lupuzor from ImmuPharma plc...
BioCentury | Apr 20, 2018
Clinical News

ImmuPharma's lupus candidate misses in Phase III

...Responder Index (SRI)-4 response at week 52 vs. placebo plus SOC (52.5% vs. 44.6%, p=0.2631). ImmuPharma...
...a phosphorylated serine at position 140. The product has Fast Track designation in the U.S. ImmuPharma plc...
...damage and safety Status: Phase III data Milestone: NA Brian Moy Lupuzor, rigerimod (CEP-33457, ipp-201101, syb l-1001, forigerimod) ImmuPharma plc...
BioCentury | Apr 17, 2018
Clinical News

ImmuPharma plummets after Phase III lupus miss

...Responder Index (SRI)-4 response at week 52 vs. placebo plus SOC (52.5% vs. 44.6%, p=0.2631). ImmuPharma...
...The product has Fast Track designation in the U.S. Brian Moy Lupuzor, rigerimod (CEP-33457, ipp-201101, syb l-1001, forigerimod) ImmuPharma plc...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...III data 2H18 Immunomedics Inc. (NASDAQ:IMMU) Sacituzumab govitecan Triple-negative breast cancer (TNBC) Submit BLA 1Q18 ImmuPharma plc...
BioCentury | Jan 5, 2017
Clinical News

Lupuzor: Completed Ph III enrollment

...200 ug subcutaneous Lupuzor every 4 weeks plus standard of care (SOC) for 48 weeks. ImmuPharma plc...
...occurrence of SLE-induced organ damage and safety Status: Completed Phase III enrollment Milestone: NA Julian Zhu CEP-33457 forigerimod IPP-201101 Lupuzor rigerimod SyB L-1001 ImmuPharma plc P140...
BioCentury | Feb 8, 2016
Financial News

ImmuPharma completes placing

ImmuPharma plc (LSE:IMM), London, U.K. Business: Autoimmune, Neurology, Infectious Date completed: 2016-02-05 Type: Placing Raised: L3.9 million ($5.5 million) Shares: 14.9 million Price: 26p Shares after offering: 121.4 million Placement agent: Panmure Gordon Investor: Institutional...
BioCentury | Feb 8, 2016
Financial News

ImmuPharma completes private placement

ImmuPharma plc (LSE:IMM), London, U.K. Business: Autoimmune, Neurology, Infectious Date completed: 2016-02-05 Type: Private placement Raised: L4.4 million ($6.3 million) Shares: 17.9 million Price: 26p Shares after offering: 121.4 million Placement agent: Panmure Gordon Investor:...
BioCentury | Aug 3, 2015
Financial News

ImmuPharma completes debt financing

...Debt financing Raised: $2 million Investor: Not disclosed Note: The financing is a convertible loan. ImmuPharma...
BioCentury | Feb 16, 2015
Clinical News

IPP-204106: Phase I/IIa data

...trial showed that the MTD of IPP-204106 was 9 mg/kg when administered with chondroitin sulfate. ImmuPharma...
...II trial of IPP-204106 to treat pancreatic cancer, but did not disclose a time frame. ImmuPharma plc...
Items per page:
1 - 10 of 63
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

...and Hongjiang Li, Staff Writers Lupuzor, rigerimod (CEP-33457, ipp-201101, P140, syb l-1001, forigerimod) Pamrevlumab (FG-3019) Revatio, Viagra, sildenafil FibroGen Inc. ImmuPharma plc Jiangsu...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...obexelimab met a secondary endpoint of longer time to loss of improvement (LOI) vs. placebo. ImmuPharma plc...
...based on modified British Isles Lupus Assessment Group (BILAG)-based combined lupus assessment (mBICLA) April 17th ImmuPharma plc...
...which mediates signaling by IFNα and other cytokines. T cell activity: Peptide analog Lupuzor from ImmuPharma plc...
BioCentury | Apr 20, 2018
Clinical News

ImmuPharma's lupus candidate misses in Phase III

...Responder Index (SRI)-4 response at week 52 vs. placebo plus SOC (52.5% vs. 44.6%, p=0.2631). ImmuPharma...
...a phosphorylated serine at position 140. The product has Fast Track designation in the U.S. ImmuPharma plc...
...damage and safety Status: Phase III data Milestone: NA Brian Moy Lupuzor, rigerimod (CEP-33457, ipp-201101, syb l-1001, forigerimod) ImmuPharma plc...
BioCentury | Apr 17, 2018
Clinical News

ImmuPharma plummets after Phase III lupus miss

...Responder Index (SRI)-4 response at week 52 vs. placebo plus SOC (52.5% vs. 44.6%, p=0.2631). ImmuPharma...
...The product has Fast Track designation in the U.S. Brian Moy Lupuzor, rigerimod (CEP-33457, ipp-201101, syb l-1001, forigerimod) ImmuPharma plc...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...III data 2H18 Immunomedics Inc. (NASDAQ:IMMU) Sacituzumab govitecan Triple-negative breast cancer (TNBC) Submit BLA 1Q18 ImmuPharma plc...
BioCentury | Jan 5, 2017
Clinical News

Lupuzor: Completed Ph III enrollment

...200 ug subcutaneous Lupuzor every 4 weeks plus standard of care (SOC) for 48 weeks. ImmuPharma plc...
...occurrence of SLE-induced organ damage and safety Status: Completed Phase III enrollment Milestone: NA Julian Zhu CEP-33457 forigerimod IPP-201101 Lupuzor rigerimod SyB L-1001 ImmuPharma plc P140...
BioCentury | Feb 8, 2016
Financial News

ImmuPharma completes placing

ImmuPharma plc (LSE:IMM), London, U.K. Business: Autoimmune, Neurology, Infectious Date completed: 2016-02-05 Type: Placing Raised: L3.9 million ($5.5 million) Shares: 14.9 million Price: 26p Shares after offering: 121.4 million Placement agent: Panmure Gordon Investor: Institutional...
BioCentury | Feb 8, 2016
Financial News

ImmuPharma completes private placement

ImmuPharma plc (LSE:IMM), London, U.K. Business: Autoimmune, Neurology, Infectious Date completed: 2016-02-05 Type: Private placement Raised: L4.4 million ($6.3 million) Shares: 17.9 million Price: 26p Shares after offering: 121.4 million Placement agent: Panmure Gordon Investor:...
BioCentury | Aug 3, 2015
Financial News

ImmuPharma completes debt financing

...Debt financing Raised: $2 million Investor: Not disclosed Note: The financing is a convertible loan. ImmuPharma...
BioCentury | Feb 16, 2015
Clinical News

IPP-204106: Phase I/IIa data

...trial showed that the MTD of IPP-204106 was 9 mg/kg when administered with chondroitin sulfate. ImmuPharma...
...II trial of IPP-204106 to treat pancreatic cancer, but did not disclose a time frame. ImmuPharma plc...
Items per page:
1 - 10 of 63